Compare HFFG & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | COYA |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United States |
| Employees | 960 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.8M | 102.7M |
| IPO Year | 2016 | 2022 |
| Metric | HFFG | COYA |
|---|---|---|
| Price | $1.67 | $4.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $15.80 |
| AVG Volume (30 Days) | 82.7K | ★ 84.8K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.65 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $1,228,282,000.00 | $7,945,753.00 |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | $763.10 |
| P/E Ratio | $23.71 | ★ N/A |
| Revenue Growth | 2.21 | ★ 123.57 |
| 52 Week Low | $1.38 | $3.71 |
| 52 Week High | $3.59 | $7.75 |
| Indicator | HFFG | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 44.45 |
| Support Level | $1.40 | $4.43 |
| Resistance Level | $1.97 | $5.19 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 6.36 | 16.02 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.